Regenimo Biosciences, Inc.

HOUSTON, TX · Founded 2025 · CIK 0002096367 · Biotech · Private

Regenerative medicine and longevity therapeutics based on cellular and molecular biology research

regenimobiosciences.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.0M
1 Form D · Nov 2025
10 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2549Mira Dx, Inc.—$2.1M
2550CellVax Therapeutics, Inc.—$2.1M
2551BACTRIA PHARMACEUTICALS LLC——
2552Regenimo Biosciences, Inc.—$2.0M
2553Venn Therapeutics, LLC——
2554Kovina Therapeutics Inc.—$2.0M
2555CUROVERSE, INC.—$2.0M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Lynda ChinDirector
  • Raju KucherlapatiDirector
  • Sharon ShachamDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.